Bradley Sitko on market cycles
From Sara Jane Demy Interviews Brad Sitko at BioFuture 2023 · · Demy-Colton
“Companies are forced to reinvent themselves, to think differently, to spend prudently. That's not a bad thing in the long run, and I think ultimately as we look back, every cycle has ended. So I think we're closer to the end of the cycle than to the beginning.”
On , Bradley Sitko, Chief Investment Officer at XOMA ROYALTY CORP, spoke about market cycles during Sara Jane Demy Interviews Brad Sitko at BioFuture 2023 on Demy-Colton.
About Bradley Sitko
In a September 2024 interview at BioFuture 2023, Bradley Sitko, Chief Investment Officer at Xoma Royalty, discussed the company's royalty model and its role in the biotech financing landscape. Sitko explained that Xoma provides capital to biotech companies in exchange for future at-risk payments from existing partnership deals, describing this as a way to "unlock the innovation of tomorrow using the innovation that was created today." He noted that there are over 600 such partnership deals annually, creating a large market for Xoma's services. Sitko stated that Xoma has completed over a dozen royalty deals and built a portfolio of more than 70 assets. Sitko also commented on the broader biotech environment, saying that companies are "forced to reinvent themselves, to think differently, to spend prudently," which he described as "not a bad thing in the long run." He expressed the view that the industry is "closer to the end of the cycle than to the beginning" and predicted that a true turnaround would occur once there is stability in the macro picture within health and life sciences. Sitko characterized Xoma's approach as offering non-dilutive financing at a stage in a company's lifecycle where it "historically hasn't been available."